What You Should Know:
– GHX, a healthcare supply chain leader announced it has entered into a definitive agreement to receive a strategic investment from private equity firm Warburg Pincus. As part of this transaction, minority investor Thoma Bravo has exited its investment. Existing investor Temasek, an investment company headquartered in Singapore, will remain the majority equity holder.
– GHX has employees in the United States, Canada and Europe and is known for operating the largest healthcare trading network representing more than 80% of licensed beds in the U.S. and more than 85% of med-surg products flow through the platform. Following its acquisition of Lumere in 2020, GHX also operates the largest unified data core of item, vendor, transaction data and clinical evidence. The company’s expertise in data and analytics helps supply chain, clinical and financial teams around the world make more informed decisions.
– The terms of the transaction were not disclosed. J.P. Morgan Securities LLC acted as exclusive financial advisor to GHX, and Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor to GHX.